Pharmacoeconmic Evaluation of Thalidomide and Calcium Dibutyryladenosine Cyclophosphate in the Treatment of Elderly Severe Psoriasis Vulgaris

OBJECTIVE To compare the pharmacoeconmic effect of thalidomide(THD) and calcium dibutyryladenosine cyclophosphate(CDC) in the treatment of elderly severe psoriasis vulgaris. METHODS The case data of patients with elderly severe psoriasis vulgaris in Dalian Dermatosis Hospital from October 1, 2016 to May 31, 2018 were collected through the HIS for a retrospective analysis, to compare the curative effects and costs of patients respectively accepting THD and CDC to treat the elderly severe psoriasis vulgaris, and then the single factor sensitivity analysis was conducted to check the stability of results. RESULTS The efficiencies of the group of patients treated with CDC and THD had no statistical difference(43.37% vs 35.00%), but the readmissions within 3 and 6 months of the THD group(86.75% & 71.08%) were significantly higher than those of the CDC group(75.00% & 57.00%), with statistical difference(P<0.05). The total cost of treatment of the THD group was 9 999.86 yuan, and that of the CDC group was 9 223.17 yuan. If taking the cost minimization analysis method and with marked effective rate as the index, the CDC group had better cost minimization; with the ratio of no recurrence within 6 months as the index, the THD group had the optimum economy(ICER=5 547.79), with sensitivity analysis showed its reliability. CONCLUSION In terms of short term curative effect, the cost of CDC is lower in the treatment of elderly severe psoriasis vulgaris, while the THD enjoys cost-effectiveness advantage in long term curative effect.